These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25715383)

  • 1. Developing a multi-criteria approach for drug reimbursement decision making: an initial step forward.
    Dionne F; Mitton C; Dempster B; Lynd LD
    J Popul Ther Clin Pharmacol; 2015; 22(1):e68-77. PubMed ID: 25715383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
    Diaby V; Lachaine J
    Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.
    Franken M; Nilsson F; Sandmann F; de Boer A; Koopmanschap M
    Pharmacoeconomics; 2013 Sep; 31(9):781-97. PubMed ID: 23839699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017.
    Skedgel C; Wranik D; Hu M
    Pharmacoeconomics; 2018 Apr; 36(4):467-475. PubMed ID: 29353385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of comparative effectiveness research in drug coverage and pricing decisions: a six-country comparison.
    Sorenson C
    Issue Brief (Commonw Fund); 2010 Jul; 91():1-14. PubMed ID: 20614655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceptable incremental cost effectiveness ratio for use of new drugs, cases in statin therapies.
    Nakao S; Kawabe H; Takuma H; Shiragami M
    Yakugaku Zasshi; 2010 Oct; 130(10):1347-52. PubMed ID: 20930487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA).
    Rutten-van Mölken M; Leijten F; Hoedemakers M; Tsiachristas A; Verbeek N; Karimi M; Bal R; de Bont A; Islam K; Askildsen JE; Czypionka T; Kraus M; Huic M; Pitter JG; Vogt V; Stokes J; Baltaxe E;
    BMC Health Serv Res; 2018 Jul; 18(1):576. PubMed ID: 30041653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges in Using MCDA for Reimbursement Decisions on New Medicines?
    Walker A
    Value Health; 2016; 19(2):123-4. PubMed ID: 27021744
    [No Abstract]   [Full Text] [Related]  

  • 10. Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).
    Wahlster P; Goetghebeur M; Kriza C; Niederländer C; Kolominsky-Rabas P;
    BMC Health Serv Res; 2015 Jul; 15():262. PubMed ID: 26152122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.
    Kwon SH; Park SK; Byun JH; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):411-419. PubMed ID: 28019130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
    Yong JH; Beca J; Hoch JS
    Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
    Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
    JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Front Public Health; 2016; 4():214. PubMed ID: 27747207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 16. Role of economic evidence in coverage decision-making in South Korea.
    Bae EY; Kim HJ; Lee HJ; Jang J; Lee SM; Jung Y; Yoon N; Kim TK; Kim K; Yang BM
    PLoS One; 2018; 13(10):e0206121. PubMed ID: 30356251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting.
    Angelis A; Montibeller G; Hochhauser D; Kanavos P
    BMC Med Inform Decis Mak; 2017 Oct; 17(1):149. PubMed ID: 29073892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement.
    West R; Borden EK; Collet JP; Rawson NS; Tonks RS
    Can J Public Health; 2002; 93(6):421-5. PubMed ID: 12448863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma.
    Chabot I; Rocchi A
    Value Health; 2010; 13(6):837-45. PubMed ID: 20561332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating Canadians' Values for Drug Coverage Decision Making.
    Rizzardo S; Bansback N; Dragojlovic N; Douglas C; Li KH; Mitton C; Marra C; Blanis L; Lynd LD
    Value Health; 2019 Mar; 22(3):362-369. PubMed ID: 30832975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.